The fact
The shares suffer brutal correction amplified by concerns over increased FDA safety alert risk for its treatments.
Wedbush firm signals deterioration of pharmacological safety outlook, questioning viability of French biotech's therapeutic pipeline.
Click the link to read an article on the topic: